Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

11Recruiting trials

Regulatory Watchboard

10 events

Aug 2026Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

Girish Dhall, MD — PHASE1

TrialNOT YET RECRUITING

Apr 2026DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins

M.D. Anderson Cancer Center

TrialNOT YET RECRUITING

Mar 2026iCanCope With NF: Innovating an Efficacious Digital Self-management and Transitional Care Program for Adolescents With Neurofibromatosis

The Hospital for Sick Children — NA

TrialNOT YET RECRUITING

Feb 2026Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — PHASE3

TrialNOT YET RECRUITING

Dec 2025Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy

Massachusetts General Hospital — NA

TrialRECRUITING

Aug 2025Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

University of Alabama at Birmingham — PHASE2

TrialRECRUITING

Sep 2024The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — PHASE2

TrialNOT YET RECRUITING

Sep 2024Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — PHASE2

TrialNOT YET RECRUITING

Jun 2024Real-World Treatment Study of Koselugo (Selumetinib)

AstraZeneca — NA

TrialRECRUITING

Feb 2024Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

Johns Hopkins University — PHASE1, PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion.
Check the disease page for updates →

Clinical Trial Landscape

11 active trials

3Phase 2

2Phase 1

4N/A

1Unknown

1PHASE1, PHASE2

11Total recruiting

Search clinical trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion →

Recent News & Research

No recent news articles indexed yet for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion.
Search PubMed for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion →

Browse all Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion news →

Specialist Network

No specialists currently listed for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion.

View all Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles